Characterization of Selective M 5 Acetylcholine Muscarinic Receptor Modulators on Dopamine Signaling in the Striatum.

Autor: Zell V; Janssen Research and Development LLC, La Jolla, California (V.Z., A.S.N., S.M., N.R., M.L., L.F., G.W., A.B., M.M., P.B., W.C.D., B.B.) and Janssen Research and Development, Janssen Pharmaceutica N.V., Beerse, Belgium (G.T.)., Teuns G; Janssen Research and Development LLC, La Jolla, California (V.Z., A.S.N., S.M., N.R., M.L., L.F., G.W., A.B., M.M., P.B., W.C.D., B.B.) and Janssen Research and Development, Janssen Pharmaceutica N.V., Beerse, Belgium (G.T.)., Needham AS; Janssen Research and Development LLC, La Jolla, California (V.Z., A.S.N., S.M., N.R., M.L., L.F., G.W., A.B., M.M., P.B., W.C.D., B.B.) and Janssen Research and Development, Janssen Pharmaceutica N.V., Beerse, Belgium (G.T.)., Mukherjee S; Janssen Research and Development LLC, La Jolla, California (V.Z., A.S.N., S.M., N.R., M.L., L.F., G.W., A.B., M.M., P.B., W.C.D., B.B.) and Janssen Research and Development, Janssen Pharmaceutica N.V., Beerse, Belgium (G.T.)., Roscoe N; Janssen Research and Development LLC, La Jolla, California (V.Z., A.S.N., S.M., N.R., M.L., L.F., G.W., A.B., M.M., P.B., W.C.D., B.B.) and Janssen Research and Development, Janssen Pharmaceutica N.V., Beerse, Belgium (G.T.)., Le M; Janssen Research and Development LLC, La Jolla, California (V.Z., A.S.N., S.M., N.R., M.L., L.F., G.W., A.B., M.M., P.B., W.C.D., B.B.) and Janssen Research and Development, Janssen Pharmaceutica N.V., Beerse, Belgium (G.T.)., Fourgeaud L; Janssen Research and Development LLC, La Jolla, California (V.Z., A.S.N., S.M., N.R., M.L., L.F., G.W., A.B., M.M., P.B., W.C.D., B.B.) and Janssen Research and Development, Janssen Pharmaceutica N.V., Beerse, Belgium (G.T.)., Woodruff G; Janssen Research and Development LLC, La Jolla, California (V.Z., A.S.N., S.M., N.R., M.L., L.F., G.W., A.B., M.M., P.B., W.C.D., B.B.) and Janssen Research and Development, Janssen Pharmaceutica N.V., Beerse, Belgium (G.T.)., Bhattacharya A; Janssen Research and Development LLC, La Jolla, California (V.Z., A.S.N., S.M., N.R., M.L., L.F., G.W., A.B., M.M., P.B., W.C.D., B.B.) and Janssen Research and Development, Janssen Pharmaceutica N.V., Beerse, Belgium (G.T.)., Marella M; Janssen Research and Development LLC, La Jolla, California (V.Z., A.S.N., S.M., N.R., M.L., L.F., G.W., A.B., M.M., P.B., W.C.D., B.B.) and Janssen Research and Development, Janssen Pharmaceutica N.V., Beerse, Belgium (G.T.)., Bonaventure P; Janssen Research and Development LLC, La Jolla, California (V.Z., A.S.N., S.M., N.R., M.L., L.F., G.W., A.B., M.M., P.B., W.C.D., B.B.) and Janssen Research and Development, Janssen Pharmaceutica N.V., Beerse, Belgium (G.T.)., Drevets WC; Janssen Research and Development LLC, La Jolla, California (V.Z., A.S.N., S.M., N.R., M.L., L.F., G.W., A.B., M.M., P.B., W.C.D., B.B.) and Janssen Research and Development, Janssen Pharmaceutica N.V., Beerse, Belgium (G.T.)., Balana B; Janssen Research and Development LLC, La Jolla, California (V.Z., A.S.N., S.M., N.R., M.L., L.F., G.W., A.B., M.M., P.B., W.C.D., B.B.) and Janssen Research and Development, Janssen Pharmaceutica N.V., Beerse, Belgium (G.T.) bbalana@its.jnj.com vzell@its.jnj.com.

Publikováno v: The Journal of pharmacology and experimental therapeutics [J Pharmacol Exp Ther] 2023 Nov; Vol. 387 (2), pp. 226-234. Date of Electronic Publication: 2023 Sep 07.

Comments to pharmacological and behavioral divergence of ketamine enantiomers by Jordi Bonaventura et al.

Autor: Chen G; Neuroscience, Janssen Research & Development, LLC, San Diego, CA, USA. GChen13@its.jnj.com., Mannens G; Drug Metabolism and Pharmacokinetics, Janssen Research & Development, Beerse, Belgium., De Boeck M; Non-Clinical Safety, Janssen Research & Development, Beerse, Belgium., Daly EJ; Neuroscience Medical Affairs, Janssen Scientific Affairs, LLC, Titusville, NJ, USA., Canuso CM; Neuroscience Clinical Development, Janssen Research & Development, LLC, Titusville, NJ, USA., Teuns G; Non-Clinical Safety, Janssen Research & Development, Beerse, Belgium., Manji H; Science for Minds, Johnson & Johnson, New Brunswick, NJ, USA., Drevets WC; Neuroscience, Janssen Research & Development, LLC, San Diego, CA, USA. wdrevets@ITS.JNJ.com.

Publikováno v: Molecular psychiatry [Mol Psychiatry] 2022 Apr; Vol. 27 (4), pp. 1860-1862. Date of Electronic Publication: 2022 Feb 17.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Nonclinical species sensitivity to convulsions: An IQ DruSafe consortium working group initiative.

Autor: DaSilva JK; Pfizer Drug Safety R&D, Pfizer, Inc, Groton, CT, USA. Electronic address: Jamie.K.DaSilva@pfizer.com., Breidenbach L; AbbVie Deutschland GmbH & Co. KG, Preclinical Safety, Knollstr, 67061 Ludwigshafen, Germany., Deats T; Sunovion Pharmaceuticals Inc., Marlborough, MA, USA., Li D; Pfizer Drug Safety R&D, Pfizer, Inc, Groton, CT, USA., Treinen K; Sunovion Pharmaceuticals Inc., Marlborough, MA, USA., Dinklo T; Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche AG, Basel, Switzerland., Kervyn S; UCB Biopharma SRL, Development Science, Braine-l'Alleud, Belgium., Teuns G; Global Safety Pharmacology, NonClinical Safety, Janssen R&D, Beerse, Belgium., Traebert M; Novartis Institutes of Biomedical Research, Novartis Pharma AG, PO Box CH-4002, Basel, Switzerland., Hempel K; Boehringer Ingelheim Pharma GmbH & Co. KG, Development NCE NDS, 88397 Biberach an der Riß, Germany.

Publikováno v: Journal of pharmacological and toxicological methods [J Pharmacol Toxicol Methods] 2020 May - Jun; Vol. 103, pp. 106683. Date of Electronic Publication: 2020 Feb 24.

Role of Kv7.2/Kv7.3 and M 1 muscarinic receptors in the regulation of neuronal excitability in hiPSC-derived neurons.

Autor: Kreir M; Non-Clinical Safety, Discovery, Product Development & Supply, Janssen Research and Development, Janssen Pharmaceutica NV, Beerse, Belgium. Electronic address: mkreir@its.jnj.com., De Bondt A; Computational Sciences, Discovery Sciences, Product Development & Supply, Janssen Research and Development, Janssen Pharmaceutica NV, Beerse, Belgium., Van den Wyngaert I; Computational Sciences, Discovery Sciences, Product Development & Supply, Janssen Research and Development, Janssen Pharmaceutica NV, Beerse, Belgium., Teuns G; Non-Clinical Safety, Discovery, Product Development & Supply, Janssen Research and Development, Janssen Pharmaceutica NV, Beerse, Belgium., Lu HR; Non-Clinical Safety, Discovery, Product Development & Supply, Janssen Research and Development, Janssen Pharmaceutica NV, Beerse, Belgium., Gallacher DJ; Non-Clinical Safety, Discovery, Product Development & Supply, Janssen Research and Development, Janssen Pharmaceutica NV, Beerse, Belgium.

Publikováno v: European journal of pharmacology [Eur J Pharmacol] 2019 Sep 05; Vol. 858, pp. 172474. Date of Electronic Publication: 2019 Jun 22.